OTC Markets OTCPK - Delayed Quote USD

Ginkgo Bioworks Holdings, Inc. (DNABW)

0.0071

-0.0003

(-4.05%)

At close: April 22 at 11:49:50 AM EDT

Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a Reconfigurable Automation Cart (RAC) system to Aura Genetics, a high-complexity diagnostic laboratory servicing the growing at-home testing and wellness market. This advanced modular laboratory automation platform will be deployed at Aura Genetics' new 22,000-square-foot high-throughput facility at the UPS Healthcare Labport, lo

PR Newswire yesterday

DNA

DNABW
-4.05%
Wall Street Analysts Think Ginkgo Bioworks (DNA) Could Surge 41.59%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Ginkgo Bioworks (DNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 13 days ago

DNA

DNABW
-4.05%
Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners Tritica Biosciences, US Pharmacopeia (USP), On Demand Pharmaceuticals, and Isolere Bio by Donaldson. This two-year program, Wheat-based High efficiency Enzyme and API Technology (WHEAT), aims to establish a new manufacturing process for the distributed production of biologic and

PR Newswire 13 days ago

DNA

DNABW
-4.05%
Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks

The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 22 days ago

DNA

DNABW
-4.05%
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)

The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks last month

DNA

DNABW
-4.05%
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why

Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

DNA

DNABW
-4.05%
Ginkgo Bioworks Holdings Full Year 2024 Earnings: EPS Misses Expectations

Ginkgo Bioworks Holdings ( NYSE:DNA ) Full Year 2024 Results Key Financial Results Revenue: US$227.0m (down 9.7% from...

Simply Wall St. last month

DNA

DNABW
-4.05%
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

PR Newswire last month

DNA

DNABW
-4.05%
Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab

Volta Labs, a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and biosecurity, today announced the integration of the Callisto™ Sample Prep System at Ginkgo Bioworks as part of the routine Illumina sequencing workflow.

PR Newswire last month

DNA

DNABW
-4.05%
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a collaboration with the European Health and Digital Executive Agency (HaDEA) as contracting authority under a joint tender of up to €24 million. The funding is made available through the EU4Health programme, linked to the key priorities of the Health Emergency Preparedness and Response Authority (HERA) of the European Commission.

PR Newswire 2 months ago

DNA

DNABW
-4.05%
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2024, on Tuesday, February 25, 2025, beginning at 5:30 p.m. ET.

PR Newswire 2 months ago

DNA

DNABW
-4.05%
Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the 2025 Ferment Series, an evolution of its flagship annual conference dedicated to advancing Ginkgo's mission of making biology easier to engineer. Throughout 2025, Ginkgo product teams will hold a series of focused Ferments at Ginkgo's beautiful event venue, located at 19 Fid Kennedy Ave in Boston's historic Seaport District, just a five-minute walk from Ginkgo's headquart

PR Newswire 2 months ago

DNA

DNABW
-4.05%
Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know

Ginkgo Bioworks (DNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 2 months ago

DNA

DNABW
-4.05%
Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bioenergy Research Center at the University of Wisconsin–Madison. This new system is designed to support the diverse needs of multiple investigators and research teams simultaneously,

PR Newswire 2 months ago

DNA

DNABW
-4.05%
Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.

PR Newswire 3 months ago

DNA

DNABW
-4.05%
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m. PT (1:30 p.m. ET).

PR Newswire 3 months ago

DNA

DNABW
-4.05%
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy

Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 4 months ago

DNA

DNABW
-4.05%
Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is part of the Advanced Research Projects Agency for Health's (ARPA-H) Resilient Extended Automatic Cell Therapies (REACT) program. Ginkgo is eligible to receive up to $9.4 mi

PR Newswire 4 months ago

DNA

DNABW
-4.05%
Ginkgo Bioworks Holdings Third Quarter 2024 Earnings: Beats Expectations

Ginkgo Bioworks Holdings ( NYSE:DNA ) Third Quarter 2024 Results Key Financial Results Revenue: US$89.0m (up 61% from...

Simply Wall St. 5 months ago

DNA

DNABW
-4.05%
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.

PR Newswire 5 months ago

DNA

DNABW
-4.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ginkgo Bioworks Holdings, Inc. (DNABW)

Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation

Wall Street Analysts Think Ginkgo Bioworks (DNA) Could Surge 41.59%: Read This Before Placing a Bet

Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain

Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks

After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)

Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why

Ginkgo Bioworks Holdings Full Year 2024 Earnings: EPS Misses Expectations

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab

Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation

Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series

Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know

Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)

Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy

Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program

Ginkgo Bioworks Holdings Third Quarter 2024 Earnings: Beats Expectations

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results